Trial Profile
A phase II non-randomised study of medroxyprogesterone acetate plus bezafibrate as adjunctive therapy in the treatment of relapsed Burkitts lymphoma in Blantyre, Malawi
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2022
Price :
$35
*
At a glance
- Drugs Bezafibrate (Primary) ; Medroxyprogesterone (Primary) ; Cyclophosphamide; Hydrocortisone; Methotrexate; Vincristine
- Indications Burkitt's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 29 Jan 2009 New trial record